BIBF 1120

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NOA-12: BIBF1120 and R-RT in Glioblastoma

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer